|
WO2001025220A1
(en)
|
1999-10-07 |
2001-04-12 |
Amgen Inc. |
Triazine kinase inhibitors
|
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
|
CA2359945C
(en)
|
1999-11-12 |
2011-04-26 |
Abbott Laboratories |
Inhibitors of crystallization in a solid dispersion
|
|
EP1257546A1
(en)
|
2000-02-17 |
2002-11-20 |
Amgen Inc. |
Kinase inhibitors
|
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
|
WO2002068398A1
(en)
|
2001-02-27 |
2002-09-06 |
Teva Pharmaceutical Industries Ltd. |
New crystal forms of lamotrigine and processes for their preparations
|
|
WO2003000235A1
(en)
|
2001-06-22 |
2003-01-03 |
Pfizer Products Inc. |
Pharmaceutical compositions of dispersions of drugs and neutral polymers
|
|
US8101629B2
(en)
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
|
JO3429B1
(ar)
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
مشتقات برميدينات مثبطة فيروس الايدز
|
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
|
ATE407678T1
(de)
|
2001-10-17 |
2008-09-15 |
Boehringer Ingelheim Pharma |
Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
|
|
SE0104140D0
(sv)
*
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
KR100875362B1
(ko)
|
2002-02-05 |
2008-12-22 |
아스텔라스세이야쿠 가부시키가이샤 |
2,4,6-트리아미노-1,3,5-트리아진 유도체
|
|
WO2003090693A2
(en)
*
|
2002-04-23 |
2003-11-06 |
Teva Pharmaceutical Industries Ltd. |
Pharmaceutical composition containing lamotrigine particles of defined morphology
|
|
AR039540A1
(es)
*
|
2002-05-13 |
2005-02-23 |
Tibotec Pharm Ltd |
Compuestos microbicidas con contenido de pirimidina o triazina
|
|
US7015227B2
(en)
|
2002-06-21 |
2006-03-21 |
Cgi Pharmaceuticals, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
|
ES2445208T3
(es)
|
2002-07-29 |
2014-02-28 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
|
|
KR101140785B1
(ko)
|
2002-08-09 |
2012-05-03 |
얀센 파마슈티카 엔.브이. |
4-〔〔4-〔〔4-(2-시아노에테닐)-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
|
|
CN1703200B
(zh)
|
2002-09-20 |
2012-02-29 |
奥尔制药公司 |
隔离亚单元和相关组合物及方法
|
|
BR0316680A
(pt)
*
|
2002-11-28 |
2005-10-18 |
Schering Ag |
Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
|
|
AU2002350719A1
(en)
*
|
2002-11-29 |
2004-06-23 |
Janssen Pharmaceutica N.V. |
Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
|
|
MXPA05007485A
(es)
|
2003-01-14 |
2006-01-30 |
Arena Pharm Inc |
Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
|
|
BRPI0407329A
(pt)
*
|
2003-02-07 |
2006-01-10 |
Janssen Pharmaceutica Nv |
Derivados de pirimidina para a prevenção de infecção de hiv
|
|
CL2004000303A1
(es)
*
|
2003-02-20 |
2005-04-08 |
Tibotec Pharm Ltd |
Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
|
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
WO2005011702A1
(en)
|
2003-07-17 |
2005-02-10 |
Tibotec Pharmaceuticals Ltd. |
Process for preparing particles containing an antiviral
|
|
BRPI0413018B8
(pt)
|
2003-07-30 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, e, uso de um composto
|
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
|
WO2005040159A1
(en)
|
2003-10-17 |
2005-05-06 |
Astrazeneca Ab |
4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
|
|
CN1930135B
(zh)
|
2004-03-05 |
2011-12-28 |
弗·哈夫曼-拉罗切有限公司 |
作为p2x3和p2x2/3拮抗剂的二氨基嘧啶
|
|
CA2580762A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as therapeutic agents
|
|
EP2289510A1
(en)
|
2004-09-20 |
2011-03-02 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
|
|
AR051091A1
(es)
|
2004-09-20 |
2006-12-20 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
|
|
AU2005286648A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
EP1807085B1
(en)
|
2004-09-20 |
2013-08-21 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
US7829712B2
(en)
|
2004-09-20 |
2010-11-09 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
|
|
CA2580857A1
(en)
|
2004-09-20 |
2006-09-28 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
EP1814878B1
(en)
|
2004-11-24 |
2012-01-04 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
PT1853588E
(pt)
|
2005-02-16 |
2008-08-25 |
Astrazeneca Ab |
Compostos químicos
|
|
ES2533258T3
(es)
*
|
2005-02-18 |
2015-04-08 |
Janssen Sciences Ireland Uc |
Derivados de óxido de 2-(4-cianofenilamino)pirimidina que inhiben el VIH
|
|
US20080214588A1
(en)
*
|
2005-03-04 |
2008-09-04 |
Herman Augustinus De Kock |
Hiv Inhibiting 2-(4-Cyanophenyl)-6-Hydroxylaminopyrimidines
|
|
TW200710091A
(en)
|
2005-04-11 |
2007-03-16 |
Tibotec Pharm Ltd |
(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
|
|
EP1899323A2
(en)
|
2005-05-16 |
2008-03-19 |
AstraZeneca AB |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
|
AU2006251163C1
(en)
|
2005-05-26 |
2012-07-12 |
Janssen Sciences Ireland Uc |
Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino benzonitrile
|
|
AU2006343359A1
(en)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
|
CA2620129C
(en)
|
2005-09-01 |
2014-12-23 |
F. Hoffmann-La Roche Ag |
Diaminopyrimidines as p2x3 and p2x2/3 modulators
|
|
WO2007025900A1
(en)
|
2005-09-01 |
2007-03-08 |
F. Hoffmann-La Roche Ag |
Diaminopyrimidines as p2x3 and p3x2/3 modulators
|
|
CA2619919C
(en)
|
2005-09-01 |
2014-04-01 |
F. Hoffmann-La Roche Ag |
Diaminopyrimidines as p2x3 and p2x2/3 modulators
|
|
WO2007049041A1
(en)
|
2005-10-28 |
2007-05-03 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
|
WO2007056205A2
(en)
*
|
2005-11-04 |
2007-05-18 |
Eastman Chemical Company |
Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
|
|
NZ572702A
(en)
*
|
2006-06-06 |
2011-09-30 |
Tibotec Pharm Ltd |
Process for preparing spray dried formulations of etravirine in microcrystalline cellulose
|
|
SI2719378T1
(sl)
|
2006-06-19 |
2016-11-30 |
Alpharma Pharmaceuticals Llc |
Farmacevtski sestavki
|
|
US20080233156A1
(en)
*
|
2006-10-11 |
2008-09-25 |
Alpharma, Inc. |
Pharmaceutical compositions
|
|
JP5464584B2
(ja)
*
|
2006-12-06 |
2014-04-09 |
ヤンセン・アールアンドデイ・アイルランド |
抗hiv化合物の臭化水素酸塩
|
|
CL2008000746A1
(es)
*
|
2007-03-14 |
2008-09-22 |
Tibotec Pharm Ltd |
Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
|
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
BRPI0811732A2
(pt)
*
|
2007-06-08 |
2014-11-18 |
Boehring Ingelheim Internat Gmbh |
Formulação de liberação prolongada de nevirapina
|
|
JP2010531301A
(ja)
*
|
2007-06-25 |
2010-09-24 |
テイボテク・フアーマシユーチカルズ |
ダルナビル及びエトラビリンを含んでなる組み合わせ調剤
|
|
WO2009051782A1
(en)
*
|
2007-10-18 |
2009-04-23 |
Concert Pharmaceuticals Inc. |
Deuterated etravirine
|
|
CN105367503A
(zh)
|
2007-10-19 |
2016-03-02 |
阿维拉制药公司 |
杂芳基化合物和其用途
|
|
US7989465B2
(en)
*
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
CA2709905A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alfred Liang |
Abuse-resistant oxycodone composition
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
JP5619743B2
(ja)
*
|
2008-08-20 |
2014-11-05 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
エテニル置換ピリジンおよびピリミジン誘導体およびウイルス感染の治療におけるそれらの使用
|
|
TW201020245A
(en)
*
|
2008-08-20 |
2010-06-01 |
Schering Corp |
Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
|
WO2010033226A1
(en)
*
|
2008-09-17 |
2010-03-25 |
Nektar Therapeutics |
Oligomer-protease inhibitor conjugates
|
|
CN101744823B
(zh)
*
|
2008-12-17 |
2013-06-19 |
广东东阳光药业有限公司 |
一种二氢嘧啶类化合物的固体分散体及其药用制剂
|
|
EP2413936B1
(en)
|
2009-03-30 |
2016-11-02 |
Janssen Sciences Ireland UC |
Co-crystal of etravirine and nicotinamide
|
|
AU2010259009A1
(en)
*
|
2009-06-08 |
2012-01-12 |
Nantbioscience, Inc. |
Triazine derivatives and their therapeutical applications
|
|
EP2342186B1
(en)
*
|
2009-06-22 |
2014-09-17 |
Emcure Pharmaceuticals Limited |
Process for synthesis of etravirine
|
|
PT2576541T
(pt)
|
2010-06-04 |
2016-07-08 |
Hoffmann La Roche |
Derivados de aminopirimidina como moduladores de lrrk2
|
|
PH12013500547A1
(en)
|
2010-09-22 |
2013-06-10 |
Arena Pharm Inc |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
HRP20172006T1
(hr)
|
2010-11-10 |
2018-02-09 |
Genentech, Inc. |
Derivati pirazol-aminopiridina kao lrrk2-modulatori
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
JP5731723B2
(ja)
*
|
2012-04-11 |
2015-06-10 |
ダウ グローバル テクノロジーズ エルエルシー |
セルロースエーテルを含む溶融押出し組成物
|
|
EP2836559B1
(en)
*
|
2012-04-11 |
2016-05-25 |
Dow Global Technologies LLC |
Composition comprising an organic diluent and a cellulose ether
|
|
JP5809379B2
(ja)
*
|
2012-04-11 |
2015-11-10 |
ダウ グローバル テクノロジーズ エルエルシー |
新規徐放剤形
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
ES2664094T3
(es)
*
|
2012-07-12 |
2018-04-18 |
Hetero Research Foundation |
Procedimiento de preparación de rilpivirina utilizando un intermedio nuevo
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MX386419B
(es)
|
2015-01-06 |
2025-03-18 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
AR100459A1
(es)
*
|
2015-05-15 |
2016-10-05 |
Química Luar S R L |
Una composición farmacéutica antiviral de uso tópico
|
|
EP3939965A1
(en)
|
2015-06-22 |
2022-01-19 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
|
|
MA47504A
(fr)
|
2017-02-16 |
2019-12-25 |
Arena Pharm Inc |
Composés et méthodes de traitement de l'angiocholite biliaire primitive
|
|
WO2018187652A1
(en)
|
2017-04-06 |
2018-10-11 |
Janssen Pharmaceutica Nv |
2,4-diaminopyrimidine derivatives as histamine h4 modulators
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
ES2987794T3
(es)
|
2018-06-06 |
2024-11-18 |
Arena Pharm Inc |
Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN115397422A
(zh)
|
2019-11-29 |
2022-11-25 |
西皮欧生命科学有限公司 |
包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
KR102145925B1
(ko)
|
2020-03-03 |
2020-08-19 |
협동조합 바이오융합기술 |
사포닌 성분이 함유된 항 바이러스용 조성물의 제조방법
|
|
CN111875548A
(zh)
*
|
2020-07-16 |
2020-11-03 |
山东大学 |
一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含fgfr抑制劑及nectin-4靶向劑之組合療法
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN116425683A
(zh)
*
|
2023-04-04 |
2023-07-14 |
上药康丽(常州)药业有限公司 |
一种米诺地尔的合成精制方法
|